Sign in
EW

Elizabeth Webster

Research Analyst at Goldman Sachs Group Inc.

New York, NY, US

Elizabeth Webster is an Equity Research Associate Analyst at Goldman Sachs, specializing in equity research across targeted industry sectors. She provides analytical coverage and investment insights on key companies relevant to her assigned industries, supporting senior analysts in producing detailed reports and recommendations. Elizabeth began her career at Goldman Sachs, developing expertise in financial modeling and in-depth industry analysis, and has contributed to the firm's research efforts since joining. She holds relevant professional credentials to operate in regulated financial roles at the firm.

Elizabeth Webster's questions to Taysha Gene Therapies (TSHA) leadership

Question · Q2 2024

Elizabeth Webster, on for Salveen Richter, inquired about the status of dialogue with regulatory authorities.

Answer

CEO Sean Nolan reported that Taysha has an upcoming Type B meeting with the FDA, a result of its RMAT designation. The key goals are to align on the cadence of interactions, share incoming clinical and natural history data in near real-time, and use this information to inform the trial design and endpoints for Part B of the study. He indicated that updates on this front would be provided in the coming quarter.

Ask follow-up questions

Fintool

Fintool can predict Taysha Gene Therapies logo TSHA's earnings beat/miss a week before the call

Let Fintool AI Agent track Elizabeth Webster for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free